working hard or hardly working ;)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PETM until we see no buyer interested PR I expect sideways trading. Also cnbc is reporting several interested buyers per documents. All of which reward shareholders. I bought calls today on that crazy drop
Quick question, if you had sept PETM 75$ calls. Would you sell on a pop or hold for possible buyout? Could this be a 200% or greater move?
you too!!
cool buddy, i'll be back next month
whats up $P? whats hot?
EDAP adding some here, beaut. consolidation off the highs.. bollies stretching higher :)
ABIO looking to move here 1.53
ABIO 1.53 looking to move here
EDAP great add day today
6$ up
GM $P enjoy your 4th as well as all the baggas
GM $P enjoy your 4th as well as all the baggas
Looking very good guys!! Still a lower market cap for what could possibly get approved this month
EDAP so thin and market cap still low.. with approval 10$ not out of question imo
Great news!! I'll be adding.
EDAP Completes FDA Inspection of Manufacturing Site
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP's manufacturing site with no findings nor issuance of Form 483 observations.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "This is another important step in the FDA PMA process for our Ablatherm-HIFU technology. It confirms and validates EDAP's ability to comply with high engineering, manufacturing and quality standards. In parallel, our team remains fully focused on preparing for the July 30, 2014 advisory committee meeting."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In February 2013, the Company introduced a new innovative HIFU device, the Focal One® dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others the uncertainties of the U.S. FDA approval process, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors/Media:
David Burke/Aaron Estrada
The Ruth Group
646-536-7009/7028
dburke@theruthgroup.com
aestrada@theruthgroup.com
EDAP!! Great news EDAP Completes FDA Inspection of Manufacturing Site
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP's manufacturing site with no findings nor issuance of Form 483 observations.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "This is another important step in the FDA PMA process for our Ablatherm-HIFU technology. It confirms and validates EDAP's ability to comply with high engineering, manufacturing and quality standards. In parallel, our team remains fully focused on preparing for the July 30, 2014 advisory committee meeting."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In February 2013, the Company introduced a new innovative HIFU device, the Focal One® dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others the uncertainties of the U.S. FDA approval process, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors/Media:
David Burke/Aaron Estrada
The Ruth Group
646-536-7009/7028
dburke@theruthgroup.com
aestrada@theruthgroup.com
GRDO looking good
gl to everyone here, come on approval!!
board is quiet today, squeeze hasn't started yet imo
A.H. 6.80!! We may have a rocket on our hands over the next few weeks. http://www.nasdaq.com/symbol/orex/after-hours
Don't forget possible euro approval later ;)
huge bids coming in now
big boys buying her here imo!! over 200 grand in buys took out 6.70
gap filled, big boys are doing some HUGE buyouts!! maybe down the road we see a huge premium buyout on Contrave fda approval? don't forget euro approval would send this into orbit imo!!
Love the bullishness on this stock!! Let's break out this week
TAKEDA huge sales force ready to push this companies product. With the added cardiac study this is a no brainer market leader on approval!! Also up for euro approval is HUGE!!
On approval I believe we see a major gap up. Personally looking for 11$ on this one, maybe higher with a squeeze in play
just sitting bids for now, see what cheaps i can pick up
This is exactly why we invest down here. Waiting for that huge runner!!
Coupled with the possible approval and shorts I do see possible 12$ +. Also digging the low ss here. If anyone watched today's trading we had huge 100k + bidders. Break 6.70 and we go to 8$ before the 11th IMHO. The shorts will be scrambling
ORFG up 20% so far!! rise from your grave!
the time to buy is here imo!! finally downside pressure subsiding and nice bids and buys coming in
GREAT DD!! smart ones are loading up by the truckload imo
ty for that great info!! this baby is about set for beast mode IMHO!!
Hope 10 baggas are enjoying a slow summer
Agreed, new highs coming and I'm still buying
HUGE DD!! This company is looking ready to rocket into big investors views shortly IMO!! Black gold. Oh and hurricane season is approaching which always boosts oil prices :)
Slow steady uptrend to new highs now IMO!!
Looking great all, missed most of the action today but added and had bids in just in case.